Chapter 10 Adrenoceptor-Activating ＆ Other Sympathomimetic

1. Chapter 10 Adrenoceptor-Activating ＆Other Sympathomimetic Cao Yongxiao曹永孝 Department of Pharmacology yxy@xjtu.edu.cn;029-82655140 http://pharmacology.xjtu.edu.cn 1

2. The Mode ＆Spectrum of Action of Sympathomimetic Drugs Drugs of indirect action are dependent on the release of catecholamines. They may have either of two different mechanisms: (1) displacement of store catecholamines from the adrenergic nerve ending or (2) inhibition of reuptake of catecholamines. Drugs of indirect action are dependent on the release of catecholamines. They have either of two different mechanisms: (1) displacement of store catecholamines from the adrenergic nerve ending. • Sympathomimetics are grouped by action mode. Some of these drugs act by direct mode, ie, they activate adrenoceptors.

3. Basic Pharmacology of Sympathomimetics • Phenylethylamine is the parent compound from which sympathomimetic drugs are derived. • This compound consists of a benzene ring with an ethylamine side chain. Substitutions may be made (1) on the terminal amino group, (2) on the benzene ring, (3) on the α or β-carbons. Substitution by -OH group at the 3 and 4 positions yield catecholamines. The of modification of phenylethylamine change the affinity of the drugs for receptors, the intrinsic ability and pharmacokinetics.

4. Receptor Types Alpha Beta Dopamine

5. Receptor Selectivity • Selectivity means that a drugs may preferentially bind to one subgroup.

6. Cardiovascular System • A. Blood Vessels • Adrenoceptors regulate vascular tone. Catecholamines are important in controlling peripheral vascular resistance and venous capacitance. • Alpha receptors increase arterial resistance, whereas β2 receptors relax smooth muscle. • There are differences in receptor types in the various vascular beds.

7. The skin vessels have predominantly αreceptors and constrict in the presence epinephrine and norepinephrine, as do the splanchnic vessels. Vessels in skeletal muscle have both αand βreceptors, which mediate constriction or dilatation, respectively.

8. D1 receptors promote vasodilation of renal, splanchnic, coronary, cerebral, and other resistance vessels. Its activation in the renal vasculature may play a major role in the natriuresis induced by dopamine.

9. B. Heart • The heart are determined largely by β1 receptors. • β-receptor activation increase calcium influx in cardiac cells. • Pacemaker activity, both normal and abnormal, is increased. • Conduction velocity in the atrio-ventricular node is increased. Intrinsic contractility is increased, and relaxation is accelerated.

10. As a result, thecardiac twitchresponse isincreasedin tension butabbreviated in duration. In the intact heart, intraventricular pressure rises and falls more rapidly, and ejection time is decreased.

11. Blood Pressure • The effects of sympathomimetic drugs on BP is based on their effects on the heart, the peripheral vascular resistance, and the venous return. • Phenylephrine, aαagonist, increases peripheral resistance and venous capacitance and rises the BP. The rise in BP increases baroreceptor-mediated vagal tone with slowing of the heart rate.

12. BP response to αand βreceptor agonist is differents. βreceptor Stimulation of βreceptor in the heart increases cardiac output. Activation of β2 receptor dilates vascular beds and decreases peripheral resistance. The net effects is to increase systolic BP and to decrease diastolic BP.

13. Eye • Phenylephrine activates αreceptors in radial muscle of the iris, causes mydriasis. αagonists increase the aqueous humor from glaucoma, being a leading cause of blindness. β stimulants relax the ciliary muscle, and decrease accommodation. Adrenergic drugs may protect neuron cells in the retina.

14. Respiratory Tract • Bronchial smooth muscle contains β2 receptors that cause bronchodilation. • The blood vessels of the respiratory tract mucosa contains αreceptors; • The decongestant action of adrenoceptor stimulants is clinically useful. snuffle

15. Gastrointestinal Tract • Beta receptors locate on the smooth muscle cells and mediate relaxation. Alpha stimulants, α2-selective agonists, decrease muscle activity by presynaptically reducing the release of ACh within the enteric nervous system. Alpha 2 receptors may also decrease slat and water flux into the lumen of the intestine.

16. Specific Sympathomimetic Drugs • Catecholamines • Epinephrineis a potent vasoconstrictor (α) and cardiac stimulant(β1). It can rise systolic BP by positive inotropic and chronotropic actions on the heart. • Epinephrine activates β2 receptors, leading to vasodilation. Consequently, total peripheral resistance and diastolic BP may fall. • Vasodilation in skeletal muscle increases blood flow during exercise.

17. Epinephrine (E)Increase heart rate, inotropy (β1) and outputVasoconstriction in systemic arteries (α)Vasodilation in muscle at low concentrations (β2); Vasoconstriction at high concentrations (α) The overall response • At low concentrations, epinephrine increases cardiac output with a small change in mean BP.  • At high concentrations, epinephrine increases BP because vasoconstriction of α-receptors offsets the β2-receptor mediated vasodilation.

18. Norepinephrine (NE) • NE and epinephrine have similar effects on β1 and αreceptors, but has relatively little effect on β2 receptors. • NE increase peripheral resistance and both diastolic and systolic BP. • Compensatory vagal reflexes tend to overcome the direct positive chronotropic effects; however, the positive inotropic effects on the heart are maintained.

19. Norepinephrine (NE)Increase heart rate(transiently) and increased inotropy (β1) directly.Vasoconstriction in systemic artery and vein (α) • The overall response is • Increase of cardiac output and systemic vascular resistance, which results in an elevation in BP. • Heart rate, although initially stimulated by NE, decreases due to activation of baroreceptor and vagal-mediated slowing of the heart rate

20. Isoproterenol • A very potent β-receptor agonist. • It activates β1 and causes positive chronotropic and inotropic actions; leading to a marked increase in cardiac output and an increase in systolic BP. It activates β2, results in vasodilation, which associate with a fall in diastolic and mean arterial pressure.

21. Dopamine (DA) • DA activates D1 receptors in vascular beds, leading to vasodilation and peripheral resistance decrease. • The effect on renal blood flow is of clinical value. • DA activates β1 in the heart. • At higher rate of infusion, DA activates vascular α receptor, • leading to vasoconstriction, including in the renal vessel, • which may mimic the actions of epinephrine.

22. Fenoldopam • is a D1 receptor agonist that selectively leads to periopheral vasodilation in some vascular beds. • The primary indication is for treatment of severe hypertension.

23. Other Sympathomimetics • They have pharmacokinetic features or relative selectivity for specific receptors. • Phenylephrinewas a relatively pure α agonist. • Because it is not a catechol derivative, it is not inactivated by COMT and has a much longer duration of action than the catecholamines. • It is an effective mydriatic and decongestant and can be used to raise the blood pressure.

24. Ephedrine • Ephedrine occurs in plants and has been used in China for over 2000 years. • Ephedrine can activate both αand βreceptors • Because ephedrine is a noncatechol, it has high bioavailabilityand a long duration of action –hours rather than minutes.

25. Clinical application • Conditions in which Blood Flow or Pressure is to be Enhanced Sympathomimetic drugs are used in hypotensive emergency on short duration αagonist such as norepinephrine, phenylephrine, methoxamine and ephedrine have been used for chronic hypotension.

26. Shock • is a complex acute cardiovascular syndrome that results in a critical reduction in perfusion of vital tissues, and usually associated with hypotension, oliguria. • The major mechanisms are hypovolemia, cardiac insufficiency, and altered vascular resistance. • sympathomimetic drugs have been used in the treatment of all forms of shock.

27. Cardiogenic Shock • usually due to decrease of cardiac output. • In low to moderate doses, positive inotropic agents such as dopamine or dobutamine may increase cardiac output and, compared with norepinephrine, cause relative little peripheral vasoconstriction. • Isoproterenol increases heart rate and work more than either dopamine or dobutamine.

28. Anaphylaxis • Anaphylactic shock affects both the cardiovascular and respiratory systems. • The syndrome includes bronchospasm, cardiac output decrease, angioedema, and hypotension. Epinephrine is the first choice drug for anaphylactic shock . β1 cardiac output systolic BP β2bronchiolar relaxes α vasoconstriction diatolic BP Capillary permeability angioedema

29. Conditions in Which Blood Flow is to be Reduced • Epinephrine is usually applied topically in nasal packs or in a gingival string. • Combining αagonists with local anesthetics greatly prolongs the duration of infiltration nerve block. • The total doses of anesthetic can be reduced. Epinephrine is the favored agent for this applicant.

30. Cardiac Applications • Isoproterenol and epinephrine have been utilized in the management of complete heart block and cardiac arrest. • Heart failure may respond to the positive inotropic effects of drugs such as dobutamine.

31. Pulmonary Applications • The most important use is in the therapy ofbronchial asthma. • Nonselective drugs, βagents, and β2-selective agents are all available for this indication. • β2-selective drugs have less adverse effects.

32. Toxicity of Sympathomimetic Drugs • The adverse effects of adrenoceptor agonist are primarily extensions of their pharmacologic effects in the cardiovascular and central nervous systems. • Adverse cardiovascular effects include marked elevations in BP that cause increased cardiac work, which may precipitate cardiac ischemia and failure.